Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational, retrospective study comapring long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in patients with Parkinson's disease

Next Previous
Search
Trial Profile

An observational, retrospective study comapring long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in patients with Parkinson's disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dopamine (Primary) ; Ropinirole (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 16 Mar 2020 New trial record
    • 09 Mar 2020 Results estimating the risk of dyskinesia and impulse control disorders in patients with Parkinson's disease prescribed ropinirole prolonged-release (R-PR) compared to those prescribed immediate-release dopamine agonists (IR-DA) as monotherapy, published in the Pharmacoepidemiology and Drug Safety

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top